The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine

Novel transdermal bioadhesive surfactant-based system for release and solubility improvement of antimalarial drugs Artemether-Lumefantrine

September 23, 2021 - 08:35 -- Open Access
Author(s): 
Volpe-Zanutto F, Fonseca-Santos B, Foglio MA, et al.
Reference: 
Biomed Mater. 2021 Sep 20

Artemether (ART) and lumefantrine (LUM) are the gold standard antimalarial drugs used for the treatment of malaria in children and pregnant women. Typically, ART and LUM are delivered orally in the form of a combined tablet, however, the appropriateness of this route of administration for these drugs is questionable due to the poor absorption and therefore bioavailability observed unless administered alongside lipid-rich foods.Transdermal drug delivery in the form of a patch-type system has been identified as a viable alternative to the conventional tablet-based therapy.

Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: a systematic review and meta-analysis of randomized control trials

August 18, 2021 - 16:18 -- Open Access
Author(s): 
Dawit Getachew Assefa, Gizachew Yismaw and Eyasu Makonnen
Reference: 
Malaria Journal 2021 20:340, 12 August 2021

Emergence of Plasmodium falciparum resistance to artemisinin and its derivatives poses a threat to the global effort to control malaria. The emergence of anti-malarial resistance has become a great public health challenge and continues to be a leading threat to ongoing malaria control efforts. The aim of this review was to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHA-PQ) compared to artemether-lumefantrine (AL) for the treatment of uncomplicated falciparum malaria among children in Africa.

An assessment of the knowledge, practices and resources during the delivery of malaria health care services among private health care practitioners: a cross section study in the Mid-Western Region of Uganda

August 17, 2021 - 15:31 -- Open Access
Author(s): 
Wanzira H, Tumwine D, Bukoma P, Musiime A, Biculu J, Ediamu T, Gudoi S, Tibenderana JK, Mulebeke R, Nantanda R, Achan J
Reference: 
BMC Health Serv Res. 2021 Aug 10;21(1):788

Approximately 50 % of the population in Uganda seeks health care from private facilities but there is limited data on the quality of care for malaria in these facilities. This study aimed to document the knowledge, practices and resources during the delivery of malaria care services, among private health practitioners in the Mid-Western region of Uganda, an area of moderate malaria transmission.

Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia

July 13, 2021 - 14:50 -- Open Access
Author(s): 
Maude RJ, Tripura R, Sovannaroth S, et al.
Reference: 
BMJ Open. 2021 Jul 7;11(7):e045900

In the Greater Mekong Subregion, adults are at highest risk for malaria. The most relevant disease vectors bite during daytime and outdoors which makes forest work a high-risk activity for malaria. The absence of effective vector control strategies and limited periods of exposure during forest visits suggest that chemoprophylaxis could be an appropriate strategy to protect forest goers against malaria.

High prevalence of P. falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine

July 6, 2021 - 13:43 -- Open Access
Author(s): 
Straimer J, Gandhi P, Renner KC, Schmitt EK
Reference: 
J Infect Dis. 2021 Jul 3:jiab352

In Southeast Asia, mutations in the Plasmodium falciparum k13 gene have led to delayed parasite clearance and treatment failures in malaria patients receiving artemisinin combination therapies. Until recently, relevant k13 mutations had been mostly absent from Africa.

Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea

June 23, 2021 - 14:06 -- Open Access
Author(s): 
Matilde Riloha Rivas, Marian Warsame, Pascal Ringwald, et al.
Reference: 
Malaria Journal 2021 20:275, 22 June 2021

Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the currently recommended first- and second-line therapies for uncomplicated Plasmodium falciparum infections in Equatorial Guinea. This study was designed to evaluate the efficacy of these artemisinin-based combinations and detect mutations in P. falciparum kelch13-propeller domain gene (Pfkelch13).

Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India

May 26, 2021 - 09:19 -- Open Access
Author(s): 
Sri Krishna, Sweta Mishra, Praveen K. Bharti, et al.
Reference: 
Malaria Journal 2021 20:229, 21 May 2021

Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria.

NOT Open Access | Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria

March 24, 2021 - 15:10 -- NOT Open Access
Author(s): 
Usman SO, Oreagba IA, Akanmu AS, et al.
Reference: 
Eur J Clin Pharmacol. 2021 Mar 23

Atazanavir-ritonavir (ATVr)-based antiretroviral therapy and artemether-lumefantrine (AL) are commonly used drugs for the treatment of human immune deficiency virus (HIV) infection and malaria respectively. However, interaction of both drugs, with Cytochrome P 3A4 (CYP 3A4) isoenzyme, may spawn clinically significant pharmacokinetic interactions. This study evaluated the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine.

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

January 31, 2021 - 15:43 -- Open Access
Author(s): 
Diarra M, Coulibaly D, Sagara I, et al.
Reference: 
Trop Med Infect Dis. 2021 Jan 24;6(1):13

In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization's standard 28-day treatment method.

Pages

Subscribe to RSS - artemether-lumefantrine